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ABSTRACT
A wide range of the epigenetic effectors that regulate chromatin modification, 
gene expression, genomic stability, and DNA repair contain structurally conserved 
domains called plant homeodomain (PHD) fingers. Alternations of several PHD finger-
containing proteins (PHFs) due to genomic amplification, mutations, deletions, 
and translocations have been linked directly to various types of cancer. However, 
little is known about the genomic landscape and the clinical significance of PHFs 
in breast cancer. Hence, we performed a large-scale genomic and transcriptomic 
analysis of 98 PHF genes in breast cancer using TCGA and METABRIC datasets and 
correlated the recurrent alterations with clinicopathological features and survival 
of patients. Different subtypes of breast cancer had different patterns of copy 
number and expression for each PHF. We identified a subset of PHF genes that was 
recurrently altered with high prevalence, including PYGO2 (pygopus family PHD finger 
2), ZMYND8 (zinc finger, MYND-type containing 8), ASXL1 (additional sex combs 
like 1) and CHD3 (chromodomain helicase DNA binding protein 3). Copy number 
increase and overexpression of ZMYND8 were more prevalent in Luminal B subtypes 
and were significantly associated with shorter survival of breast cancer patients. 
ZMYND8 was also involved in a positive feedback circuit of the estrogen receptor 
(ER) pathway, and the expression of ZMYND8 was repressed by the bromodomain 
and extra terminal (BET) inhibitor in breast cancer. Our findings suggest a promising 
avenue for future research—to focus on a subset of PHFs to better understand the 
molecular mechanisms and to identify therapeutic targets in breast cancer.
INTRODUCTION
Histone modifications, such as methylation and 
acetylation, play critical roles in chromatin function, 
transcriptional regulation, genomic stability, and DNA 
repair [1, 2]. These epigenetic modifications are mediated 
by sets of enzymatic complexes that have complementary 
but opposing functions, namely the “writers,” which 
catalyze methylation and acetylation in a site-specific 
manner, and the “erasers,” which remove the modification 
marks [1, 2]. Such modification marks are interpreted 
by “reader” proteins that recognize and are recruited to 
the modified histone [3, 4]. One of the largest families 
of epigenetic effectors capable of “reading” post-
translationally modified or unmodified histone tails 
consists of plant homeodomain (PHD) fingers. They recruit 
various nuclear complexes to chromatin and stabilize them 
[3, 5]. Among PHD finger-containing proteins (PHFs), 
the PHD finger exists singly or in multiple copies, in 
the absence of or in conjunction with other functional 
modules, such as distinct histone “reading” domains, 
e.g., bromo-, chromo-, and Tudor domains, or a catalytic 
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histone-associating module, such as ATPase, SET 
(Suppressor of variegation, Enhancer of zeste, Trithorax), 
and Jumonji C domains [4, 5]. PHFs can be broadly 
divided into the following three subgroups based on 
their additional functional domains and biological roles: 
“Epigenetic Writers,” including histone methyltransferases 
and acetyltransferases; “Epigenetic Erasers,” including 
histone demethylases; and “Epigenetic Readers.” Thus, 
PHFs are vital players in regulating and maintaining the 
physiological functioning of epigenetic modifications in 
a highly context-dependent manner. Consequently, when 
PHFs malfunction, they are implicated in a broad range of 
human diseases, including cancer.
Breast cancer is the most common malignant 
disease in women, with more than 240,000 new cases 
diagnosed and 40,000 deaths in the United States per 
year. This heterogeneous disease is categorized into five 
molecular subtypes: Luminal A, Luminal B, epidermal 
growth factor receptor 2–enriched (HER2+), basal-like, 
and normal-like breast cancers [6, 7]. The majority of 
breast cancers (~70%) belong to the Luminal (A and B) 
subtypes, characterized by expression of the estrogen 
receptor-α (ERα). ERα is the principal biomarker for 
directed hormone therapies and is the primary therapeutic 
target in breast cancer [8]. Luminal B breast cancers have 
lower expression of ERα and higher histologic grade, and 
they are less responsive to hormone therapy and have 
poorer outcomes than Luminal A [9]. Furthermore, basal-
like breast cancer usually occurs in young women and is 
a highly aggressive subtype associated with very poor 
prognosis [10]. By deeply understanding the genetic and 
epigenetic alterations that are associated with the different 
types of breast cancer, we can identify new druggable 
subtype-specific targets for effective therapies.
Recent studies revealed that tumors, including 
breast cancer, have frequent genetic alterations in histone 
modifiers, including PHFs [18-20]. PHD fingers have 
been shown to play a critical role in oncogenic drivers; 
for example, a chromosomal translocation in the PHD 
finger of PHF23 or lysine (K)-specific demethylase 5A 
(KDM5A) was implicated in acute myeloid leukemia 
[11, 12]. We demonstrated that KDM4C and KDM5A are 
frequently amplified and overexpressed in breast cancer, 
particularly in aggressive basal-like subtypes [13, 14]. 
The PHD fingers in histone lysine methyltransferase 
WHSC1 (Wolf-Hirschhorn syndrome candidate 1) 
are critical for recruiting WHSC1 to oncogenic gene 
loci and driving multiple myeloma [15]. WHSC1L1, 
a homolog of WHSC1, is significantly amplified and 
overexpressed in a subset of breast, lung, and pancreatic 
cancers [16, 17]. Furthermore, the bromodomain PHD 
finger transcription factor (BPTF) is amplified and 
overexpressed in melanomas, and BPTF is required for 
c-MYC transcriptional activity and in vivo tumorigenesis 
[18]. In contrast, a chromodomain helicase DNA binding 5 
(CHD5) gene, which encodes an ATPase-dependent DNA-
binding protein with two PHDs, is a tumor suppressor 
in neuroblastomas. PHD-mediated histone 3 binding is 
required for CHD5-mediated tumor suppression [19, 20]. 
In addition, the additional sex combs like 1 (ASXL1) is one 
of the most frequently mutated genes in malignant myeloid 
diseases, and ASXL1 mutations are strongly associated 
with a poor prognosis in these myeloid disorders [21, 22].
The initiation and progression of hematological 
malignancies and solid tumors have been associated 
with dysregulation of several PHFs. However, little is 
known about the rest of the genomic landscape and the 
clinical significance of PHFs in breast cancer. Thus, 
we performed a comprehensive, integrated genomic 
and transcriptomic analysis of 98 PHF genes in breast 
cancer and identified associations among recurrent copy 
number alteration, gene expression, clinicopathological 
features, and survival of patients. This approach enabled 
us to identify a subset of PHF genes that were recurrently 
altered with high prevalence, such as PYGO2 (pygopus 
family PHD finger 2), ZMYND8 (zinc finger and MYND 
[myeloid, Nervy, and DEAF-1] domain containing 
8), ASXL1, and CHD3 (chromodomain helicase DNA 
binding protein 3). High expression of ZMYND8 was 
significantly correlated with patient survival and was 
likely involved in a positive feedback circuit of the ER 
pathway in breast cancer. Furthermore, we found that JQ-
1, a bromodomain and extra terminal (BET) inhibitor, 
suppressed ZMYND8 expression in breast cancer. These 
findings prioritize a subset of PHFs for future research 
focused on understanding molecular mechanisms and 
therapeutic potentials in breast cancer.
RESULTS
Copy number and expression profiling of PHFs 
in breast cancer
Genetic alterations, including copy number alteration 
(CNA) and somatic mutation, are a universal hallmark of 
cancer [23, 24]. We hypothesized that PHFs with recurrent 
genetic alterations might play important roles in different 
types of breast cancer and hence serve as novel therapeutic 
targets. Based on the current ChromoHub database, there 
are 99 PHFs in the human genome (Supplementary 
Figure S1 and Table S1) [25]. We first analyzed CNAs 
and mutations in 98 PHF genes (excluding KDM5D on 
chromosome Yq11) compiled from 960 breast cancer 
specimens in The Cancer Genome Atlas (TCGA) via 
cBioPortal [26, 27]. The copy number for each PHF was 
generated by the copy number analysis algorithm GISTIC 
(Genomic Identification of Significant Targets in Cancer) 
and categorized, as copy number level per gene, into 
the following: high-level amplification, low-level gain, 
diploid, heterozygous deletion, and homozygous deletion 
[26, 27]. We first grouped the copy number of each PHF 
gene of TCGA breast cancer samples into amp/gain 
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(high-level amplification and low-level gain), diploid, 
and deletion (heterozygous or homozygous deletions). 
As shown in Table 1 and Supplementary Table S2, the 11 
most frequently (>40%) amplified/gained PHF genes were 
KDM5B, ASH1L, PYGO2, PHF20L1, CREBBP, FBXL19, 
DIDO1, ZMYND8, PHF20, ASXL1, and BPTF; and the 
9 most frequently (>40%) deleted genes were PHF23, 
CHD3, RAI1, KMT2A, TCF20, PHF21B, PHF11, EP300, 
and BRD1. The most frequently (>1.5%) mutated PHF 
genes were KMT2C, KMT2D, CHD4, ASH1L, ASXL3, 
ASXL2, KMT2A, and BAZ2B. Notably, ASH1L exhibited 
a higher frequency of both amp/gain (73.93%) and 
mutation (1.77%), whereas CHD3 and KMT2A showed 
higher frequency of both genetic deletion (61% and 
49.01%, respectively) and mutation (1.46% and 1.67%, 
respectively) in breast cancer (Table 1 and Supplementary 
Figure S2).
We next examined the mRNA expression levels 
of each PHF in TCGA breast cancer samples. As shown 
in Table 1 and Supplementary Table S2, we found that 
three PHFs (PYGO2, KDM5B, and PHF20L1) were 
overexpressed at the mRNA level (Z-score > 1) in more 
than 40% of breast cancers. PYGO2 had the highest 
frequency (51.41%) of mRNA overexpression. In contrast, 
the most deleted gene, PHF23, had the highest frequency 
(43.48%) of mRNA underexpression (Z-score < -1), and 
CHD3 was underexpressed in 35.14% of TCGA breast 
cancer samples. We also analyzed the correlation between 
copy number and mRNA level of 97 PHFs (excluding 
those of KDM5D and KMT2B, as their RNA-sequencing 
data were not available) from TCGA breast cancer 
specimens. As shown in Supplementary Table S3, almost 
all PHF genes had positive correlations between DNA 
copy number and mRNA expression, and 24 of them had 
a Spearman correlation coefficient (r) > 0.5.
To determine whether the genetic alteration or 
mRNA expression of each PHF is specific to a breast 
cancer subtype, we analyzed CNA and mRNA expression 
independently across different subtypes of 808 breast 
cancer samples for which PAM50 (Prediction Analysis 
for Microarray 50) subtype data were available [26]. The 
frequencies of high-level amplification, low-level gain, 
diploid, heterozygous deletions, homozygous deletions, 
and somatic mutation of PHF genes in five breast 
cancer subtypes are shown in Supplementary Table S4. 
mRNA expression status of the PHF genes is shown in 
Supplementary Table S5. Among the 11 most amplified/
gained PHF genes, 7 (PYGO2, KDM5B, PHF20L1, 
ASH1L, PHF20, DIDO1, and ASXL1) likely had a higher 
frequency of gain/amplification in both Luminal and basal 
subtypes of breast cancer, and 4 of them (ZMYND8, BPTF, 
CREBBP, and FBXL19) were more commonly amplified/
gained in Luminal, particularly Luminal B breast cancer, 
than in the normal-like subtype (Figure 1A, Supplementary 
Table S4). Among the 9 most deleted PHF genes, PHF23, 
CHD3, RAI1, and PHF11 had more deletions in Luminal, 
HER2+, or basal-like subtypes, while KMT2A, TCF20, 
PHF21B, EP300, and BRD1 had more deletions in the 
Luminal B subtype (Figure 1B, Supplementary Table 
S4). A detailed analysis of expression levels of each 
PHF in the five breast cancer subtypes also revealed that 
expression levels of PYGO2 and KDM5B were higher 
in Luminal, HER2+, and basal-like, compared with 
their expression levels in the normal-like subtype of 
breast cancer (Figure 1, Supplementary Figure S3, and 
Supplementary Table S5). We also found that ZMYND8 
has a higher expression level in Luminal and HER2+, but 
not in the basal-like subtype, compared with that in the 
normal-like subtype breast cancer (Figure 1). In contrast, 
the commonly deleted genes CHD3 and KMT2A showed 
underexpression in HER2+ and basal-like subtypes 
(Figure 1, Supplementary Table S5).
To validate our findings from  TCGA breast cancer 
dataset regarding PHF genetic alterations, we conducted 
an independent analysis using the METABRIC dataset, 
which contains approximately 2000 primary breast 
cancers with long-term clinical follow-up data. We 
found that 17 PHF genes, including PYGO2, KDM5B, 
PHF20L1, and ZMYND8, had a higher frequency (>10%) 
of gain/amplification, and 9 PHF genes, including CHD3 
and PHF23, had a higher frequency of deletion in the 
METABRIC breast cancer samples (Supplementary 
Table S6), although the frequency of gain/amplification 
identified in the METABRIC dataset is lower than that 
of  TCGA dataset, possibly due to the different CNA 
analysis platforms and calling algorithms. Furthermore, 
statistical analyses of copy number alterations in 
METABRIC dataset define 32 regions of amplification and 
13 regions of deletion [28]. We analyzed these 45 genomic 
regions and found that 11 PHF genes are localized in 
significantly amplified regions, including KDM5A in 
1q32, WHSC1L1 and ASH2L in 8p11-12, PHF20L1 in 
8q13-24, and ZMYND8 in 20q13 (Supplementary Table 
S7). We also found that Luminal B breast cancer had 
the highest frequency of ZMYND8 gain/amplification in 
the METABRIC dataset (Supplementary Figure S4A). 
Expression levels of PYGO2, KDM5B, PHF20L1, 
and ZMYND8 were also significantly higher in tumor 
samples compared to that in non-tumor breast tissue 
(Supplementary Table S8). Again, mRNA expression 
levels of PYGO2 and KDM5B were higher in Luminal, 
HER2+, and basal-like breast cancers, and ZMYND8 was 
higher in Luminal B and HER2+ subtypes compared with 
that in the normal-like subtype in the METABRIC dataset 
(Supplementary Figure S4B; p < 0.001).
Recurrent mutations of CHD3-5 and ASXL1-3 
genes in breast cancer
Among mutated PHF genes in TCGA breast cancer 
samples, we found that 33 PHF genes contained mutations 
in the PHD domains (Supplementary Table S9). We 
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noticed that three PHF subfamilies (KMT2A/C/D, ASXL1-
3, and CHD3-5) had higher frequencies of mutation. We 
also analyzed frequencies of mutation number per gene 
size, and found that the higher frequent mutation ratios 
were associated with KMT2C, CHD4, ASXL2, and BAZ2B, 
which have mutations of more than 2 per kilobase (kb) 
(Supplementary Table S9). We previously reported a 
mutation spectrum for KMT2C and KMT2D and proposed 
their function as tumor suppressors in breast cancer [29]. 
Here, we focused on analyzing the mutation spectrum of 
ASXL1-3 and CHD3-5 genes in breast cancer.
The ASXL family consists of three members 
(ASXL1, ASXL2 and ASXL3) that share a common domain 
architecture: HARE-HTH, ASXH, and a C-terminal PHD. 
As shown in Figure 2A and Supplementary Table S10, we 
identified a total of 40 ASXL family mutations, consisting 
of 7 mutations of ASXL1, 17 mutations of ASXL2, and 16 
mutations of ASXL3. One tumor sample (TCGA-BH-A0B9) 
Table 1: Frequency (%) of genetic and transcriptional alterations of PHFs that are highly prevalent in TCGA breast 
cancers
Gene Location
DNA Alterations mRNA Expression Levels
Amp/Gain Diploid Deletion Mutation Z  
Score >= 1
1>Z  
Score > -1
Z  
Score <= -1
PYGO2 1q21.3 73.62 25.03 1.36 0.10 51.41 41.92 6.67
KDM5B 1q32.1 75.81 22.63 1.56 1.25 46.09 48.80 5.11
PHF20L1 8q24.22 59.65 35.56 4.80 0.73 41.40 52.03 6.57
ASH1L 1q22 73.93 24.50 1.56 1.77 37.96 51.51 10.53
CREBBP 16p13.3 53.49 38.16 8.34 1.46 32.64 55.16 12.20
BPTF 17q24.2 41.50 46.40 12.10 1.36 32.01 53.81 14.18
DIDO1 20q13.33 48.38 47.13 4.48 0.94 31.60 55.16 13.24
PHF20 20q11.22-q11.23 44.11 50.89 5.01 0.31 27.53 59.12 13.35
ZMYND8 20q13.12 46.72 48.80 4.48 0.52 19.60 69.45 10.95
FBXL19 16p11.2 52.03 39.62 8.34 0.21 19.29 70.91 9.80
ASXL1 20q11.21 42.44 52.87 4.69 0.52 27.53 58.29 14.18
ASXL2 2p23.3 14.91 67.15 17.94 1.67 17.62 64.03 18.35
ASXL3 18q12.1 15.33 55.89 28.78 1.67 2.19 97.81 0.00
CHD3 17p13.1 5.53 33.47 61.00 1.46 6.26 58.60 35.14
CHD4 12p13.31 25.23 60.38 14.39 2.09 19.29 64.65 16.06
CHD5 1p36.31 7.30 53.28 39.42 1.46 1.67 98.33 0.00
KMT2A 11q23.3 9.38 41.61 49.01 1.67 10.74 63.82 25.44
KMT2C 7q36.1 24.71 55.47 19.81 6.99 15.95 68.72 15.33
KMT2D 12q13.12 20.13 65.69 14.18 2.40 17.62 64.23 18.14
BAZ2B 2q24.2 8.45 69.86 21.69 1.56 12.41 69.03 18.56
BRD1 22q13.33 12.20 42.54 45.26 0.63 11.05 55.89 33.06
EP300 22q13.2 10.32 44.00 45.67 1.15 12.20 64.13 23.67
PHF11 13q14.2 7.61 46.30 46.09 0.31 9.38 61.21 29.41
PHF21B 22q13.31 11.37 42.34 46.30 0.31 3.86 96.14 0.00
TCF20
22q13.3; 
22q13.2
10.84 42.75 46.40 1.46 12.10 62.46 25.44
RAI1 17p11.2 7.92 37.02 55.06 0.42 9.28 59.54 31.18
PHF23 17p13.1 5.11 33.37 61.52 0.21 6.67 49.84 43.48
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Figure 1: Frequencies of PYGO2 and ZMYND8 copy number increase A., and CHD3 and KMT2A deletion B. across five subtypes 
of TCGA breast cancer samples. C. Expression levels of PYGO2, ZMYND8, CHD3, and KMT2A across five subtypes of TCGA breast 
cancer samples. The differences in PYGO2, ZMYND8, CHD3, and KMT2A mRNA levels among breast cancer subtypes are statistically 
significant (p < 0.05).
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Figure 2: Mutational spectra of ASXL1-3 and CHD3-5 genes in breast cancer. The images show protein domains and the 
positions of somatic mutations in ASXL1-3 A. and CHD3-5 B. in TCGA breast cancers. A red dot indicates a nonsense mutation, frameshift 
deletion, insertion, or splice; a green dot indicates a missense mutation; and a black dot indicates an inframe insertion or deletion. The data 
were obtained from TCGA database via cBioPortal.
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had three missense mutations (D893H, E1006K, and 
G1198V) in the ASXL1 gene, and one sample (TCGA-
AN-A046) had two nonsense mutations (R357* and R312*) 
in the ASXL2 gene. Most of the mutations in the ASXL genes 
are localized to the amino-terminal end of the PHD domain. 
Previous studies demonstrated that truncation mutations 
of ASXLs occur in autism, Bohring–Opitz and related 
syndromes, hematological malignancies, and several solid 
tumors [21, 22, 30]. Therefore, we predict that mutations at 
the amino terminus of the PHD might result in the gain or 
loss of function of ASXL proteins in breast cancer.
CHD3, CHD4, and CHD5 belong to the second 
subfamily of CHD proteins, which are characterized by 
an SNF2-like domain located in the central region as well 
as tandem PHD and chromodomains at their C-termini 
[31, 32]. The SNF2-like domain is responsible for ATP-
dependent chromatin remodeling. As shown in Figure 2B 
and Supplementary Table S11, we identified a total of 51 
CHD3-5 family mutations, consisting of 14 mutations 
of CHD3, 22 mutations of CHD4, and 15 mutations of 
CHD5, most of which were missense mutations. In the 
CHD4 gene, tumor sample TCGA-C8-A27B had two 
missense mutations (P90Q and A235P), and TCGA-
D8-A1JN had one missense mutation (I989F) and an 
X34 splice. In the CHD5 gene, one sample (TCGA-D8-
A1JK) had a missense mutation (H1820Y) and frameshift 
deletion (G976Afs*11). Furthermore, we found that one 
sample (TCGA-BH-A1FC) had a mutation (D407H) in the 
region of the first PHD-finger of CHD3 (Figure 2B).
Association of PHF gene expression with clinical 
features and survival of breast cancer patients
To investigate the clinical relevance of PHF 
alterations in breast cancer, we examined expression 
levels of each PHF gene at different stages of TCGA 
breast cancer samples. The means of Z-score and p-value 
for each PHF gene across four American Joint Committee 
on Cancer (AJCC) stages of breast cancer are shown in 
Supplementary Table S12. Among 11 most commonly 
amplified/overexpressed PHF genes, we found that three 
genes, ZMYND8, PHF20, and DIDO1, were significantly 
highly expressed in advanced-stage breast cancers 
(T-test: Stage I+II vs III+IV; p < 0.05; Figure 3A and 
Supplementary Table S12). Because several PHFs were 
more commonly amplified/gained in the Luminal subtype 
of breast cancer, we then examined the expression levels 
of each PHF gene in different stages of only Luminal 
breast cancer samples. We found that ZMYND8 and 
PHF20, but not DIDO1, also had significantly higher 
expression in advanced stages of Luminal breast cancers 
(p < 0.05; Supplementary Table S13).
Next, to analyze the relationship between PHF 
mRNA expression and overall survival of breast cancer 
patients, samples were divided into high (Z-score > 
0) and low (Z-score =< 0) groups based on the mRNA 
expression level of each PHF. Supplementary Table S14 
summarizes the results of a log-rank statistical analysis of 
97 PHFs in breast cancer. High mRNA levels of ZMYND8, 
BPTF, PHF20, WHSC1L1, and PHF20L1 were positively 
associated with shorter survival in breast cancer patients 
(p < 0.05) (Figure 3B, Supplementary Table S14). We 
also performed survival analyses of each PHF gene in 
Luminal (A and B) subtypes only. In the Luminal subtype, 
we found that high mRNA levels of six PHF genes, 
PHF20, PYGO1, KDM5A, PHF6, BPTF, and CHD5, were 
significantly associated (p < 0.05) with shorter survival in 
breast cancer patients. Conversely, low mRNA levels of 
KDM4B and ING were significantly associated (p < 0.05) 
with shorter survival (Supplementary Table S15). We then 
performed a multivariate analysis to investigate whether 
the expression level of each PHF was predictive of poor 
prognosis compared with standard prognostic markers, 
including age at diagnosis, ER status, progesterone 
receptor status, HER2 status, tumor size, lymph node 
status, metastasis status, and molecular subtype (basal vs. 
non-basal). In addition to PHF20L1, which we previously 
reported, we also found that high mRNA level of ZMYND8 
(p = 0.034, hazard ratio [HR] = 1.92) was independently 
associated with shorter survival of TCGA breast cancer 
patients (Figure 3C) [33]. Validating this analysis using 
the METABRIC dataset, we found that ZMYND8 was 
similarly highly expressed in breast cancer samples of 
advanced stage and higher grade (Supplementary Figure 
S5). We confirmed that higher expression of ZMYND8 was 
correlated with a poor prognosis (p = 0.034, HR = 1.16) in 
METABRIC breast cancer samples.
ZMYND8 in the feedback circuit of the ER 
pathway was suppressed by the BET inhibitor
In our analysis of the genetic alterations of PHFs 
in breast cancer, we found that ZMYND8 had a higher 
frequency of amplification and overexpression in 
Luminal B breast cancer, and its overexpression was 
associated with shorter survival in patients in both 
TCGA and METABRIC datasets. We further examined 
ZMYND8 expression in a panel of breast cancer cells. 
Quantitative reverse transcription PCR (qRT-PCR) and 
RNA sequencing showed that ZMYND8 was expressed 
more in ER-positive Luminal than ER-negative basal 
cell lines (Figure 4A and Supplementary Figure S6). 
Because a previous study demonstrated that ZMYND8 
physically binds ERα in breast cancer [34], and because 
we found that mRNA levels of ZMYND8 were positively 
correlated with expression levels of the ESR1 (estrogen 
receptor 1) gene (Spearman correlation coefficient (r) of 
0.34 in TCGA breast cancer samples), we tested whether 
ZMYND8 is a downstream target of the ER pathway. 
We treated two ER-positive Luminal breast cancer cell 
lines, T47D and ZR75-1, with tamoxifen, the most widely 
used nonsteroidal selective ER modulator for adjuvant 
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Figure 3: A. Expression levels of ZMYND8 across different AJCC stages of TCGA breast cancer samples. B. Kaplan-Meier plots of 
overall survival associated with mRNA expression levels of ZMYND8 in TCGA breast cancers. C. Multivariate analysis revealed that 
ZMYND8 expression was independent of prognostic variables influencing overall survival of TCGA breast cancer patients.
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Figure 4: A. mRNA expression levels of ZMYND8, measured by qRT-PCR, in a panel of 21 breast cancer cell lines. mRNA expression 
levels in the immortalized but nontumorigenic breast epithelial cell line MCF10A cells were arbitrarily set as 1. Cell lines: green indicates 
MCF10A; blue, Luminal breast cancer cell lines; pink, HER2+ breast cancer cell lines; and red, basal-like breast cancer cell lines. B. qRT-
PCR and C. immunoblot analysis of ZMYND8 expression after treatment with tamoxifen (TAM) in T47D and ZR75-1 cells (*p < 0.05 and 
**p < 0.01, Student’s t-test). Protein levels of ERα were also measured by western blot after TAM treatment.
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therapy of ER-positive breast cancer. Supplementary 
Figure S7 shows that expressions of ERα target genes 
TFF1 (trefoil factor 1) and MYB were suppressed in T47D 
cells after tamoxifen treatment. We found that expression 
of ZMYND8 at mRNA and protein levels was also 
significantly reduced in those two cell lines after tamoxifen 
treatment (Figure 4B and 4C). Next, we analyzed 
published data of ERα chromatin immunoprecipitation 
sequencing (ChIP-Seq) in ER-positive breast cancer cell 
lines [35, 36]. We found that ERα directly bound to the 
genomic regions of the ZMYND8 gene. Supplementary 
Figure S8 illustrates ChIP-Seq binding sites of ERα at the 
ZMYND8 genomic loci in T47D cells [36, 37]. Thus, these 
data suggest that a positive regulatory loop between ERα 
and ZMYND8 exists in ER-positive luminal breast cancer.
Recent studies demonstrated that bromodomain-
containing protein-4 (BRD4) plays an important role in 
promoting estrogen-regulated transcription of ER-positive 
breast cancer cells [38]. BRD4 is a member of the BET 
family, which also includes BRD2, BRD3, and BRDT. 
BRD4 is a major target of BET inhibitors, such as JQ-
1, which also suppress breast cancer growth inhibition in 
vitro and in vivo [39]. We validated that JQ-1 inhibited 
growth and survival of both ER-positive luminal T47D 
and basal-like SUM159 breast cancer cells (Figure 5A 
and 5B). The Western blot assays demonstrated that 
JQ-1 downregulated c-MYC, a known target of BRD4, 
but there was no measurable effect on ERα expression in 
T47D cells (Figure 5C and Supplementary Figure S9). We 
also found that JQ-1 dramatically suppressed the mRNA 
and protein expression of ZMYND8 in both ER-positive 
T47D and ER-negative SUM159 cells (Figure 5C and 
5D). Thus, ZMYND8 expression is likely regulated by 
multiple mechanisms, including gene amplification, ERα, 
and possibly BRD4 pathways in breast cancer.
DISCUSSION
By conducting integrated genomic and transcriptomic 
analyses of breast cancers with different molecular 
subtypes and clinicopathological features, we identified 
a subset of PHF genes, including PGYO2, CHD3, and 
ZMYND8, that have high frequencies of CNA and altered 
mRNA expression. Different subtypes of breast cancer had 
different patterns of copy number and expression of each 
PHF. Several PHF genes, e.g. PYGO2, were amplified/
overexpressed likely independent of subtype. Copy number 
increase and overexpression of ZMYND8 were more 
prevalent in Luminal B subtypes and were significantly 
associated with shorter survival of breast cancer patients. 
Interestingly, we found that ZMYND8, which physically 
binds ERα, is a downstream target of ERα, suggesting 
that ZMYND8 is in a positive feedback circuit of the ER 
pathway in breast cancer. Furthermore, the expression of 
ZMYND8 was repressed after treatment with the BET 
inhibitor JQ-1 in breast cancer cells.
The PHD finger, which is approximately 50-
80 amino acids long, is a sequence-specific histone 
recognition protein domain [5]. The PHD finger consists 
of two anti-parallel β-sheets and a C-terminal α-helix, 
which is stabilized by two zinc atoms. Biochemically, 
PHD fingers are classified into canonical PHD fingers 
that bind to trimethylated histone H3 lysine 4 (H3K4me3) 
or noncanonical PHD fingers that bind to differently 
modified histones or DNA. H3K4me3 is a histone mark 
associated with active transcription. PHD binding of 
H3K4me3 occurs through an aromatic cage, similar to 
those observed in chromodomain, PWWP (Pro-Trp-Trp-
Pro), and Tudor domains [4, 5]. Of note, one tryptophan 
(Trp) residue in the second β-strand of canonical PHD is 
absolutely conserved; this Trp forms one of the walls of 
the aromatic cage for H3K4me3 binding [5]. In contrast, 
noncanonical PHD fingers that bind unmodified histone 
H3 lack the second β-strand Trp. Among 99 PHF proteins 
with PHD fingers based on the current ChromoHub 
database, 57 proteins, including PYGO2, contain only one 
PHD, and most of them bind H3K4me3 (Supplementary 
Table S1). Thirty-two PHF proteins, e.g. CHD3-5, have 
two PHDs, and many of them, particularly those with two 
PHDs in tandem, bind unmodified histone H3, due to the 
lack of conserved Trp residues in both PHDs. In addition, 
11 PHF proteins have more than two PHDs; one of them is 
histone methyltransferase KMT2C, which has eight PHDs, 
and likely has diverse histone-binding and biological 
roles [40]. Furthermore, many PHFs also have additional 
epigenetic effector domains, including bromo-, chromo-, 
Tudor, and PWWP domains. We found the coexistence of 
a PHD and bromodomains in 22 PHF proteins, including 
BPTF and ZMYND8; thus, that pairing is considerably 
more frequent than the pairing of any other epigenetic 
effector domains. Bromodomain is a “reader” of lysine 
acetylation [39]. A combined readout of epigenetic marks 
by the PHD and bromodomain has been characterized 
in several PHFs [4, 41]. For example, the PHD finger 
domain of BPTF recognizes methylation signatures at 
H3K4me2/3, and the bromodomain selectively binds 
to the H4K16ac acetylation mark [41]. Thus, structure-
function studies have highlighted the fact that PHD fingers 
recognize histone tails with relatively high specificity 
and affinity, making them critical components of various 
epigenetic mechanisms.
In this study, we identified four PHFs, PYGO2, 
KDM5B, PHF20L1, and ASH1L, which were most 
commonly amplified/overexpressed in breast cancer 
(Table 1). These data agree with and consolidate prior 
reports on the genetic alterations and oncogenic potentials 
of these PHFs in various tumors. PYGO2 protein contains 
one PHD domain, which regulates β-catenin-mediated 
transcription through an interaction with methylated 
H3K4 marks [42, 43]. Recent studies demonstrated that 
PHD-mediated PYGO2 chromatin binding supports 
and enhances mammary gland progenitor proliferation 
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Figure 5: A. Representative images of cells stained with crystal violet show the effect of JQ-1 on growth and survival of ER-positive T47D 
and ER-negative SUM159 cells. B. Bar graphs show relative cells growth after JQ-1 treatment in T47D and SUM159 cells. C. Immunoblot 
and D. qRT-PCR analysis of ZMYND8 expression after treatment with JQ-1 in T47D and SUM159 cells (*p<0.05 and **p<0.01, Student’s 
t-test). Protein levels of MYC were also measured by western blot after JQ-1 treatment in T47D and SUM159 cells.
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[44, 45]. Furthermore, loss of epithelial Pygo2 delayed 
mammary tumor onset in mouse mammary tumor virus 
(MMTV)-Wnt1 transgenic mice [46]. KDM5B was 
originally discovered as a gene that was upregulated by 
HER2 in breast cancer cells [47]. Consistent with this, 
we found that the mRNA expression level of KDM5B 
was slightly higher in the HER2+ subtype, compared 
with luminal and basal-like subtypes, in both TCGA and 
METABRIC breast cancer samples (Supplementary Figure 
S3). Inhibiting KDM5B in breast cancer cells has been 
shown to reduce proliferation-reduced mammary tumor 
growth in vitro and in vivo [48, 49]. In addition, COLT 
analysis of the genes essential for cancer cell survival and 
proliferation in 29 breast cancer lines identified KDM5B 
as a hit in 12 (41%) of these lines (Supplementary Table 
S16) [50]. PHF20L1 protein contains two types of histone-
reading modules, PHD and Tudor domains. PHF20L1 is 
amplified and overexpressed in a subset of basal-like and 
Luminal B breast cancers. We recently demonstrated that 
knockdown of PHF20L1 inhibits cell proliferation in breast 
cancer cell lines [33]. We speculate that PHF20L1 likely 
functions as a critical tethering factor, via its PHD and 
Tudor domains, to regulate DNA and histone methylation 
signals in breast cancer [33]. ASH1L, a member of the 
trithorax group, is the H3K36 methyltransferase. A recent 
study demonstrated that ASH1L is a crucial regulator of 
key leukemia target genes and contributes to leukemia 
pathogenesis [51]. Thus, these four PHFs are most likely 
proto-oncogenes in breast cancer.
In breast cancer, the two most commonly deleted/
underexpressed PHF genes were PHF23 and CHD3. 
Fusion of the PHF23 gene with the NUP98 (Nucleoporin 
98) gene frequently recurs in acute myeloid leukemia [11]. 
PHF23 protein contains the canonical PHD finger at the 
C-terminus, and the PHD finger is retained in the NUP98-
PHF23 fusion. The leukemogenic potential of the NUP98-
PHF23 fusion protein relies on the ability of the PHD finger 
to recognize the H3K4me3/2 marks [12]. CHD3, CHD4, 
and CHD5 proteins, which share common ATPase domains, 
tandem PHD domains, and chromodomains, are catalytic 
components of the NuRD (nucleosome remodeling histone 
deacetylase) complex [31]. CHD3 and CHD4 are expressed 
ubiquitously in every normal tissue, whereas CHD5 is 
preferentially expressed in the nervous system and testis. 
Both CHD3 and PHF23 genes are localized at 17p13.1, the 
TP53 region. A recent study demonstrated that deletions 
linked to TP53 loss drive cancer through p53-independent 
mechanisms [52]. In that study, a shRNA library targeting 
the ~100 protein-coding genes (excluding TP53) in mouse 
chromosome 11B3 syntenic to human 17p13.1 was screened 
for its tumor-suppressor activity in mouse models. Among 
17 identified genes, CHD3 and PHF23 were considered 
potential tumor suppressors [52]. In the future, it will be 
important to determine how CHD3 and PHF23 play tumor-
suppressor roles in a p53-dependent or independent manner 
in breast cancer.
In contrast to CHD3 and CHD5, which most likely 
function as tumor suppressors, the role of CHD4 in 
various tumors appears to be quite complex. It exhibits 
both oncogenic and tumor-suppressing properties [20, 
31, 53-55]. Biochemically, the two PHD fingers of CHD4 
are able to bind two distinct H3 tails with unmodified 
H3K4 and/or H3K9me3, but not H3K4me3 [56]. As the 
major component of NuRD, CHD4 has been implicated in 
regulating gene transcription and facilitating DNA repair 
[55, 56]. Compelling evidence indicates that CHD4 is a 
biomarker of drug sensitivity in cancer cells. For example, 
using high-throughput genomics, Geeleher et al. revealed 
that expression of CHD4 predicted the sensitivity of the 
histone deacetylase (HDAC) inhibitor Vorinostat in a 
large panel of cancer cell lines [57]. Furthermore, global 
proteomic analysis of the NCI-60 cancer cell lines revealed 
that the CHD4 protein is the second most recurrent and 
significant protein associated with the sensitivity of 97 
different drugs [58]. Depletion of CHD4 sensitizes the 
CAMA1 breast cancer cell line to Vorinostat or leukemia 
cells to genotoxic agents and reduces tumor formation 
[53, 57]. In contrast to CHD3, the expression level of 
CHD4 was higher in Luminal, HER2+, and basal-like 
breast cancer compared with normal-like breast cancers 
(Supplementary Figure S10). Thus, CHD4 appears to play 
various roles in tumorigenesis and in the development of 
drug resistance.
In a recent study of 560 breast cancer samples with 
the whole-genome sequences, Nik-Zainal et al. identified 
93 protein-coding cancers carrying probable driver 
mutations [59]. Five of them (KMT2C, KMT2D, ASXL1, 
CREBBP, and PHF6) were PHF genes. Our previous 
study, together with others, demonstrated that KMT2C 
and KMT2D function as tumor suppressors [29, 60]. 
The ASXL1 is frequently mutated in a range of myeloid 
malignancies [21, 22]. Most cancer-associated ASXL1 
mutations give rise to truncated proteins that retain 
the amino-terminal BAP1 (BRCA1 associated protein 
1)-interacting region of ASXL1, but lose the carboxy-
terminal PHD domain [21, 22, 61]. Accumulating data 
suggest that ASXL1 functions as a haploinsufficient tumor 
suppressor in the hematopoietic system [61]. In contrast, 
other studies suggested that ASXL1 mutations might 
confer a gain-of-function, rather than loss-of-function, 
by generating a stable truncated protein lacking the PHD 
domain that either serves as a dominant negative function 
or generates a new function [61]. In this study, we also 
found that ASXL1 gene, localized at 20q11 region, is 
commonly amplified/gained in breast cancer (Table 1). 
Thus, functional roles of ASXL1 might be altered by gene 
amplification or gain-of-function mutations in a set of 
breast cancer.
A finding of particular interest from our study is the 
dysregulation of ZMYND8 in a subset of breast cancers. 
The ZMYND8 protein, which contains an N-terminal 
PHD-bromo-PWWP (PBP) cassette and a C-terminal 
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MYND (Myeloid-Nervy-DEAF1) domain (Supplementary 
Figure S11), has a wide range of interacting partners, 
including transcription factors, chromatin remodeling 
complexes, and histone demethylase/deacetylase 
enzymes. Analysis of the human endogenous coregulatory 
complexome revealed that the PBP cassette of ZMYND8 
interacts directly with ERα, and both co-occupy a set of 
genomic sites of known ERα-binding sites [34]. Results of 
gene expression and reporter assay studies confirmed the 
coactivator functions of ZMYND8 for ER transcriptional 
activity [34]. A recent study revealed that ZMYND8 reads 
the dual histone modifications H3K4me1-H3K14ac via 
PHD-bromo cassette, and it is associated with repression 
of metastasis-linked genes [62]. The MYND domain 
of ZMYND8 is responsible for its interactions with the 
NuRD complex, notably the core catalytic component 
CHD4 [54]. Importantly, ZMYND8 has been identified as 
a new DDR (DNA Damage Response) factor; ZMYND8 
recruits CHD4 to the sites of DNA damage and represses 
transcription and facilitates DNA repair by homologous 
recombination [54, 63]. Thus, ZMYND8 is implicated 
in both transcriptional activation and silencing, as well as 
DNA damage in a context-specific manner. In the present 
study, we provided additional evidence that ZMYND8 was 
involved in a positive feedback circuit involving the ER 
pathway in breast cancer, where the interaction between 
ZMYND8 and ERα promotes activation of the ERα target 
gene, including ZMYND itself. Furthermore, an additional 
regulatory mechanism, such as BRD4’s association with 
super-enhancers, might regulate ZMYND expression in 
both ER-positive and ER-negative breast cancers. It is 
worth noting that, based on the NCBI database, at least 
18 transcript variants of ZMYND8 exist. Western blot 
also revealed the additional protein bands with molecular 
weight lower than full-length ZMYND8 in breast cancer 
cell lines, particularly Luminal subtypes (Supplementary 
Figure S12). Furthermore, fusion of ZMYND8 has 
been identified in lymphoma and breast cancer; both of 
the ZMYND8 fusions reportedly remove the MYND 
domain but retain the N-terminal PBP cassette [64, 65]. 
ZMYND8 gene is localized at chromosomal region 20q13, 
which also contains candidate breast cancer oncogenes: 
MYBL2 (MYB proto-oncogene like 2), ZNF217 (zinc 
finger protein 217), and AURKA (aurora kinase A) [66]. 
As shown in Supplementary Figure S13, we found that 
most ZMYND8-amplified breast cancer samples also 
showed the amplification of other candidate oncogenes 
at the 20q13 region. It is necessary to further investigate 
whether and how ZMYND8 contribute, independently or 
cooperatively with other 20q13-amplified genes, to breast 
tumorigenesis.
In conclusion, our integrated genomic and 
transcriptomic analysis identified a broad spectrum of 
genetic alterations in PHF genes involved in different 
subtypes of breast cancer. Given the higher prevalence of 
genomic and transcriptomic alteration of several PHFs, 
such as PYGO2, ZMYND8, ASXL1, and CHD3, it is 
necessary to further characterize their structures, roles, 
and the molecular mechanisms of the PHD domain that 
are implicated in breast cancer initiation and progression. 
Furthermore, inhibition of critical epigenetic reader 
domains, such as PHD fingers, is emerging as the next 
frontier in epigenetic drug development. A few inhibitors 
that target PHD fingers, e.g., PYGO2-PHD and the third 
PHD of KDM5A, have been reported recently [67, 68]. 
We anticipate that our findings, along with similar studies 
on other types of tumors, will help prioritize which PHFs 
to study in order to better understand the molecular 
mechanisms and discover novel therapeutic targets in 
oncology.
MATERIALS AND METHODS
Cell culture
The cultures for the SUM series of breast cancer 
cell lines and the nontransformed human mammary 
epithelial cell line MCF10A were described previously 
[69]. The Colo824 cell line was obtained from DSMZ 
(Braunschweig, Germany), SUM cell lines were obtained 
from Dr. Stephen P. Ethier, and all other cell lines in this 
study were obtained from ATCC (Manassas, VA, USA). 
Cell growth was assessed by using an MTT assay. For 
clonogenic survival assays, cells were seeded in 12-well 
dishes and treated with JQ-1. After 12 days for SUM159 
cells or 20 days for T47D cells, colonies were fixed and 
stained with 0.5% crystal violet. Cells were photographed 
and counted with an automated mammalian cell colony 
counter (Oxford Optronix GELCOUNT, Oxford, United 
Kingdom).
The cancer genome atlas (TCGA) data for breast 
cancer
The DNA copy number, mutation, and overall 
survival datasets of 960 breast cancer samples used in this 
research were obtained from the cBio Cancer Genomics 
Portal [26, 27]. For each PHF, the copy number was 
generated from the copy number analysis algorithm 
GISTIC (Genomic Identification of Significant Targets in 
Cancer) and categorized as copy number level per gene: 
“-2” is a deep loss (possibly a homozygous deletion), “-1” 
is a heterozygous deletion, “0” is diploid, “1” indicates 
a low-level gain, and “2” is a high-level amplification. 
For mRNA expression data, the relative expression of an 
individual gene and the distribution of a gene’s expression 
in a reference population were analyzed. The reference 
population was either all tumors that are diploid for the 
gene in question or, when available, normal adjacent 
tissue. The returned value indicates the number of 
standard deviations away from the mean of expression 
in the reference population (Z-score). Somatic mutation 
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data were obtained from exome sequencing [26, 27]. 
Breast cancer subtype and clinicopathologic information 
were extracted via the UCSC Cancer Genomics Browser 
(genome-cancer.ucsc.edu) and the cBio Cancer Genomics 
Portal [6, 26, 27]. Among the 960 breast cancer samples, 
808 had subtype data available, including 22 normal-like, 
405 Luminal A, 185 Luminal B, 66 HER2+, and 130 
basal-like breast cancers [26, 33, 70].
The METABRIC (molecular taxonomy of breast 
cancer international consortium) dataset
The METABRIC dataset contains approximately 
2000 primary breast cancers with long-term clinical 
follow-up data. METABRIC normal breast expression 
dataset (n = 144) was used as a non-cancer, tissue control. 
A detailed description of the dataset is presented in the 
original publication [28]. The CNAs and normalized 
expression data of METABRIC were downloaded with 
access permissions from the European Genome-phenome 
Archive (https://www.ebi.ac.uk/ega) under accession 
number EGAC00000000005. In the METABRIC dataset, 
copy number log
2
 ratios were segmented using two 
analytical methods, circular binary segmentation and an 
adapted hidden Markov model. The median of the log
2
 
ratio was computed, and gene-centric alterations were 
categorized as amplification, gain, heterozygous loss, and 
homozygous loss. The data for 98 PHFs were based on 
the circular binary segmentation–derived copy number 
profiles [28]. The normalized gene expression profiles 
were generated using the Illumina Human HT-12 platform 
[28].
Semiquantitative PCR reactions
mRNA was prepared from human breast cancer 
cell lines and the MCF10A cell line by using an RNeasy 
Plus Mini Kit (QIAGEN). mRNA was mixed with qScript 
cDNA SuperMix (Quanta Biosciences, Gaithersburg, 
MD, USA) then converted into cDNA through a reverse-
transcription (RT) reaction for real-time PCR reactions. 
Primer sets were ordered from Life Technologies 
(Carlsbad, CA, USA). A PUM1 primer set was used as a 
control. Semiquantitative RT-PCR was performed using 
the FastStart Universal SYBR Green Master (Roche 
Diagnostics, Indianapolis, IN, USA).
Immunoblotting and antibodies
Whole-cell lysates were prepared by scraping cells 
from dishes into cold RIPA lysis buffer. After centrifugation 
at high speed, protein content was estimated by the 
Bradford method. A total of 20–50 μg of total cell lysate 
was resolved by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis and transferred onto a polyvinylidene 
difluoride membrane. Antibodies used in the study 
included anti-ZMYND8 (1:1000, Bethyl Laboratories 
A302-089A, Montgomery, TX, USA), anti-MYC 
(1:1000, Cell Signaling D3N8F, Danvers, MA, USA), 
anti-ERα (1:1000, Cell Signaling 8644, Danvers, MA), 
anti-β-actin (1:5000, Sigma-Aldrich A5441, St. Louis, 
MO), and anti-β-tubulin (1:5000, Sigma-Aldrich T8328, 
St. Louis, MO, USA).
Statistical analysis
Statistical analyses were performed using R 
software (http://www.r-project.org) and Graphpad Prism 
(version 6.03). Correlations between copy numbers and 
mRNA levels of each PHF from TCGA breast cancer 
specimens were analyzed using Spearman, Kendall, and 
Pearson correlation tests. The Spearman and Kendall tests 
are rank correlations—the Spearman coefficient relates the 
two variables while conserving the order of data points, 
and the Kendall coefficient measures the number of ranks 
that match in the data set. We used the “cor” function in 
R statistical software for computation, specifying in the 
code which type of test we wanted (Spearman, Kendall, 
or Pearson). The significance of difference in mRNA 
expression level for each PHF among different subtypes 
and stages of breast cancer samples was calculated using 
ANOVA and Welch’s t-test. To analyze the relationships 
between PHF mRNA expression and overall patient 
survival in breast cancer, samples were divided into 
higher and lower expression groups of each PHF, based 
on mRNA expression Z-scores [RNA-Seq V2 RSEM 
(RNA-Seq by Expectation-Maximization)] in TCGA 
dataset or the log
2
 normalized expression level in the 
METABRIC dataset. Multivariate survival analysis was 
conducted in TCGA breast cancer samples using the Cox 
regression function (“coxph”) in R. Factors included in 
the multivariate analysis model were age at diagnosis 
(continuous variable), ER status (positive vs. negative), 
progesterone receptor status (positive vs. negative), HER2 
status (positive vs. negative), tumor size (>20 mm vs. ≤20 
mm), lymph node status (positive vs. negative), metastasis 
status (positive vs. negative), and PAM50 subtype (basal 
vs. non-basal).
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